Dr Reddy's announces launch of OTC tablets in US market

Pharma major Dr Reddy's Laboratories today said it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride extended release tablets in the US market.

Mumbai: Pharma major Dr Reddy's Laboratories today said it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride extended release tablets in the US market.

The company has launched over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride extended release tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D in the US market on November 18, a statement issued here said.

Dr Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA). The Allegra-D 12 Hour brand has US sales of approximately USD 49.8 million for the latest 52 weeks ending October 6 for total US multi outlet.

Dr Reddy's Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg is available in a 20 count blister, the release said.
Shares of the company closed marginally up at Rs 3,519.25 on BSE today.

Zee News App: Read latest news of India and world, bollywood news, business updates, cricket scores, etc. Download the Zee news app now to keep up with daily breaking news and live news event coverage.